Moderna Schedules June 25 Science Day, FDA Flu Shot Debate, German Facility Plans
MRNA•Moderna will host its Science Day investor event at 9:00am ET on June 25 to showcase its AI- and robotics-accelerated mRNA research pipeline. The company faces an FDA VRBPAC meeting on June 18 to review its experimental mRNA flu vaccine and explores investing in shuttered BioNTech production plants in Germany.
1. Science Day Investor Event
Moderna will host its Investor Event - Science Day at 9:00am ET on June 25, 2026. The company will present an overview of its mRNA research and early development programs, emphasizing its AI and robotics integration to accelerate new therapeutic innovations.
2. FDA Panel to Review Flu Vaccine
The FDA’s Vaccines and Related Biological Products Advisory Committee will convene on June 18 to debate approval of Moderna’s experimental mRNA flu vaccine. A favorable recommendation could pave the way for a first-of-its-kind RNA-based influenza shot.
3. German Production Investment Plans
CEO Stephane Bancel has signaled interest in acquiring production capacity in Germany by targeting sites slated for closure by BioNTech. This move could expand Moderna’s manufacturing footprint in Europe and support future mRNA vaccine output.
